

Revision date: 06-Apr-2010 Version: 2.0 Page 1 of 8

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

Animal Health Division (office hours): +44 (0)1737 331333

Material Name: Methylprednisolone Tablets

Trade Name: MEDROL

Chemical Family: Corticosteroid hormone

Intended Use: Pharmaceutical active used as anti-inflammatory

2. HAZARDS IDENTIFICATION

Appearance: Tablets, varying in color depending on strength

Signal Word: DANGER

Statement of Hazard: May damage the unborn child.

May cause damage to blood and blood forming organs through prolonged or repeated

exposure.

Short Term: May be absorbed through the skin and cause systemic effects.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and

blood forming organs. May cause allergic reactions in susceptible individuals following

repeated contact with this material.

Known Clinical Effects: Adverse clinical reactions include the development of hypersensitivity and/or irritation leading

to rashes, itching, and burning. Clinical use has resulted in hormonal alterations.

EU Indication of danger: Toxic to reproduction: Category 1

Harmful

EU Hazard Symbols:



EU Risk Phrases:

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

R61 - May cause harm to the unborn child.

Australian Hazard Classification

(NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Material Name: Methylprednisolone Tablets Page 2 of 8 Version: 2.0

Revision date: 06-Apr-2010

2. HAZARDS IDENTIFICATION

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Methylprednisolone	83-43-2	201-476-4	T;R48/22	2, 4, 8, 16 or
			Repr.Cat.1;R61	32mg***
Calcium stearate	1592-23-0	216-472-8	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	*
Mineral oil	8012-95-1	232-384-2	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Lactose	63-42-3	200-559-2	Not Listed	*
Sorbic acid	110-44-1	203-768-7	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical **Eye Contact:**

attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Symptoms and Effects of Exposure:

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May include oxides of carbon.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Not applicable Fire / Explosion Hazards:

Material Name: Methylprednisolone Tablets

Revision date: 06-Apr-2010

Version: 2.0

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken,

avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Methylprednisolone

Pfizer OEL TWA-8 Hr: 4 μg/m³, Skin

Calcium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA **Australia TWA** 10 mg/m³ Listed **Belgium OEL - TWA** Ireland OEL - TWAs Listed Lithuania OEL - TWA Listed Portugal OEL - TWA Listed Spain OEL - TWA Listed Sweden OEL - TWAs Listed

Corn Starch

ACGIH Threshold Limit Value (TWA)

Australia TWA

Belgium OEL - TWA

Bulgaria OEL - TWA

Czech Republic OEL - TWA

Greece OEL - TWA

Listed

OSHA - Final PELS - TWAs: 15 mg/m³ total 5 mg/m³

Portugal OEL - TWA Listed
Spain OEL - TWA Listed

Mineral oil

Material Name: Methylprednisolone Tablets

Revision date: 06-Apr-2010

Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

ACGIH Threshold Limit Value (TWA) 5 mg/m³ TWA
ACGIH Threshold Limit Value (STEL) 10 mg/m³ STEL

ACGIH OELs - Notice of Intended Changes Listed 5 mg/m³ **Australia TWA Belgium OEL - TWA** Listed **Bulgaria OEL - TWA** Listed Czech Republic OEL - TWA Listed **Denmark OEL - TWA** Listed Finland OEL - TWA Listed Listed **Greece OEL - TWA Ireland OEL - TWAs** Listed **Netherlands OEL - TWA** Listed **OSHA - Final PELS - TWAs:** 5 mg/m³ Listed **Poland OEL - TWA** Listed Portugal OEL - TWA Listed Romania OEL - TWA Spain OEL - TWA Listed Sweden OEL - TWAs Listed

Sucrose

10 mg/m³ TWA **ACGIH Threshold Limit Value (TWA) Australia TWA** 10 mg/m³ **Belgium OEL - TWA** Listed **Bulgaria OEL - TWA** Listed Estonia OEL - TWA Listed France OEL - TWA Listed **Ireland OEL - TWAs** Listed Latvia OEL - TWA Listed Lithuania OEL - TWA Listed **OSHA - Final PELS - TWAs:** 15 mg/m³ total

Fortugal OEL - TWA Spain OEL - TWA Listed Listed

Analytical Method: Analytical method available for methylprednisolone. Contact Pfizer Inc for further information. Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

Material Name: Methylprednisolone Tablets

Revision date: 06-Apr-2010

Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:TabletsColor:VariousMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD50 29.7 g/kg

Lactose

Rat Oral LD50 > 10 g/kg

Sorbic acid

Rat Oral LD50 7360 mg/kg Mouse Oral LD50 3200 mg/kg

Methylprednisolone

Rat Oral LD 50 > 2000 mg/kg Mouse Oral LD 50 450 mg/kg

Rat Intraperitoneal LD 50 1000 mg/kg Mouse Intraperitoneal LD 50 1409 mg/kg Rat Subcutaneous LD 50 >3000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Mineral oil

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Methylprednisolone

Skin Irritation Rabbit No effect Eye Irritation Rabbit No effect

Skin Sensitization - GPMT Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Page 6 of 8

Material Name: Methylprednisolone Tablets

Revision date: 06-Apr-2010 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Methylprednisolone

42 Day(s) Dog Oral 167 μg/kg/day LOAEL Adrenal gland

6 Week(s) Rat Subcutaneous 500 μg/kg/day LOAEL None identified

14 Week(s) Rat Subcutaneous 0.4 μg/kg/day NOAEL Blood forming organs, Adrenal gland 52 Week(s) Rat Subcutaneous 4 μg/kg/day NOAEL Blood forming organs Adrenal gland

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Methylprednisolone

Reproductive & Fertility Rat Subcutaneous 0.004 mg/kg/day NOAEL Paternal toxicity Reproductive & Fertility Rat Subcutaneous 0.02 mg/kg/day LOAEL Fetotoxicity

Embryo / Fetal Development Rat Subcutaneous 1.0 mg/kg/day LOAEL Fetotoxicity, Teratogenic

Embryo / Fetal Development Mouse Intramuscular 330 mg/kg/day LOAEL Teratogenic Embryo / Fetal Development Rabbit Intramuscular 0.1 mg/kg/day LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Methylprednisolone

Bacterial Mutagenicity (Ames) Salmonella Negative
Unscheduled DNA Synthesis Rat Hepatocyte Negative

Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative

Direct DNA Interaction Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Mineral oil

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Material Name: Methylprednisolone Tablets

Revision date: 06-Apr-2010

Version: 2.0

15. REGULATORY INFORMATION

EU Symbol:

EU Indication of danger: Toxic to reproduction: Category 1

Harmful

EU Risk Phrases:

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

R61 - May cause harm to the unborn child.

EU Safety Phrases:

S36/37 - Wear suitable protective clothing and gloves.

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:

DANGER

May damage the unborn child.

May cause damage to blood and blood forming organs through prolonged or repeated exposure.

Canada - WHMIS: Classifications

WHMIS hazard class: D2a very toxic materials



Methylprednisolone

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedStandard for the Uniform SchedulingSchedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 201-476-4

Calcium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Listed

Present

obligations of Register:

EU EINECS/ELINCS List 216-472-8

Corn Starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

obligations of Register:

EU EINECS/ELINCS List 232-679-6

Lactose

Material Name: Methylprednisolone Tablets

Revision date: 06-Apr-2010

Version: 2.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

200-559-2

Mineral oil

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

232-384-2

Sorbic acid

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

203-768-7

Sucrose

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedREACH - Annex IV - Exemptions from thePresent

obligations of Register:

EU EINECS/ELINCS List 200-334-9

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R61 - May cause harm to the unborn child.

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 -

Disposal Considerations.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet